Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 6/2006

01-11-2006 | Original Article

Providers’ HIV Prevention Discussions with HIV-Seropositive Injection Drug Users

Authors: James D. Wilkinson, Wei Zhao, Scott Santibanez, Julia Arnsten, Amy Knowlton, Cynthia A. Gómez, Lisa R. Metsch, INSPIRE Study Group

Published in: AIDS and Behavior | Issue 6/2006

Login to get access

Abstract

Public health agencies have recommended incorporating HIV prevention counseling into the medical care of persons living with HIV/AIDS. Injection drug users (IDUs) especially need HIV risk-reduction counseling because of their high risk for HIV transmission through both sexual and injection behaviors. The objective of this study was to assess the prevalence of, and patient factors associated with, the delivery of HIV prevention messages to HIV-seropositive IDUs in primary care settings. A majority of participants reported having an HIV prevention discussion with their provider during their most recent primary care visit. Factors significantly associated with report of such discussion were being Hispanic or non-Hispanic Black; high school education or less; and better perception of engagement with provider. Medical providers should provide prevention messages to all HIV-seropositive IDUs, regardless of demographic factors. Effective HIV prevention interventions in primary care settings, including interventions to improve patient-provider communication, are needed for HIV-seropositive IDUs.
Literature
1.
Bakken, S., Holzemer, W. L., Brown, M., Powell-Cope, G. M., Turner, J. G., and Inouye, J. (2000). Relationships between perception of engagement with health care provider and demographic characteristics, health status, and adherence to therapeutic regimen in persons with HIV/AIDS. AIDS Patient Care and STDs, 14, 189–197.PubMedCrossRef
2.
Centers for Disease Control and Prevention. (2002). HIV/AIDS Surveillance Report, 14.
3.
Centers for Disease Control and Prevention. (2003). Incorporating HIV prevention into the care of persons living with HIV: Recommendations of the Centers for Disease Control and Prevention, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of America. MMWR Morbidity and Mortality Weekly Reports, 52(RR–12), 1–24.
4.
Deren, S., Beardsley, M., Coyle, S., and Singer, M. (1998). HIV serostatus and risk behaviors in a multisite sample of drug users. Journal of Psychoactive Drugs, 30, 239–245.PubMed
5.
Derogatis, L. R., and Spencer, P. M. (1982). The Brief Symptom Inventory (BSI): Administration, scoring, and procedural manual. Baltimore: John Wiley.
6.
Dodge, W. T., BlueSpruce, J., Grothaus, L., Rebolledo, V., McAfee, T. A., and Carey, J. W. (2001). Enhancing primary care HIV prevention: A comprehensive clinical intervention. American Journal of Preventive Medicine, 20, 177–183.PubMedCrossRef
7.
Duffus, W. A., Barragan, M., Metsch, L., Krawczyk, C. S., Loughlin, A. M., and Gardner, L. I. (2003). Effect of physician specialty on counseling practices and medical referral patterns among physicians caring for disadvantaged human immunodeficiency virus–infected populations. Clinical Infectious Diseases, 36, 1577–1584.PubMedCrossRef
8.
Gerbert, B., Brown, B., Volberding, P., Cooke, M., Caspers, N., and Love, C. (1999). Physicians’ transmission prevention assessment and counseling practices with their HIV positive patients. AIDS Education and Prevention, 11, 307–320.PubMed
9.
Gerbert, B., Moe, J. C., Saag, M. S., Benson, C. A., Jacobsen, D. M., and Feraios, A. (2001). Toward a definition of HIV expertise: A survey of experienced HIV physicians. AIDS Patient Care and STDs, 15, 321–330.PubMedCrossRef
10.
Marks, G., Richardson, J. L., Crepaz, N., Stoyanoff, S., Milam, J., and Kempker, C. (2002). Are HIV providers talking with patients about safer sex and disclosure?: A multi–clinic assessment. AIDS, 16, 1953–1957.PubMedCrossRef
11.
Margolis, A. D., Wolitski, R. J., Parsons, J. T., and Gomez, C. A. (2001). Are healthcare providers talking to HIV–seropositive patients about safer sex? AIDS, 15, 2335–2337.PubMedCrossRef
12.
McGowan, J. P., Shah, S. S., Ganea, C. E., Blum, S., Ernst, J. A., and Irwin, N. K. (2004). Risk behavior for transmission of human immunodeficiency virus (HIV) among HIV–seropositive individuals in an urban setting. Clinical Infectious Diseases, 38, 122–127.PubMedCrossRef
13.
Meredith, K. L., Jeffe, D. B., Mundy, L. M., and Fraser, V. J. (2001). Sources influencing patients in their HIV medication decisions. Health Education and Behavior, 28, 40–50.PubMed
14.
Metsch, L. R., McCoy, C. B., Lai, S., and Miles, C. (1998). Continuing risk behaviors among HIV–seropositive chronic drug users in Miami, Florida. AIDS and Behavior, 2, 161–169.CrossRef
15.
Metsch, L. R., Pereyra, M., del Rio, C., Gardner, L., Duffus, W., and Dickinson, G. (2004). Delivery of HIV prevention counseling by physicians at HIV medical care settings in 4 US cities. American Journal of Public Health, 94, 1186–1192.PubMedCrossRef
16.
Morin, S. F., Koester, K. A., Steward, W. T., Maiorana, A., McLaughlin, M., and Myers, J. J. (2004). Missed opportunities: prevention with HIV–infected patients in clinical care settings. Journal of Acquired Immune Deficiency Syndromes, 36, 960–966.PubMed
17.
Purcell, D. W., Metsch, L. R., Latka, M., Santibanez, S., Gomez, C. A., and Eldred, L. (2004). Interventions for seropositive injectors–research and evaluation: An integrated behavioral intervention with HIV–seropositive injection drug users to address medical care, adherence, and risk reduction. Journal of Acquired Immune Deficiency Syndromes, 37, S110–S118.PubMed
18.
Richardson, J. L., Milam, J., McCutchan, A., Stoyanoff, S., Bolan, R., Weiss, J., Kemper, C., Larsen, R. A., Hollander, H., Weismuller, P., Chou, C., and Marks, G. (2004). Effect of brief safer–sex counseling by medical providers to HIV–1 seropositive patients: a multi–clinic assessment. AIDS, 18, 1179–1186.PubMedCrossRef
19.
Rogers, E. S., Chamberlin, J., Ellison, M. L., and Crean, T. (1997). A consumer–constructed scale to measure empowerment among users of mental health services. Psychiatric Services, 48, 1042–1047.PubMed
20.
Stewart, A. L., and Camberg, C. J. (1992). Physical functioning measures. In: A. L. Stewart, J. E. Ware (Eds.), Measuring functioning and well–being: The medical outcomes study approach (pp. 86–101). Durham: Duke University Press.
21.
Tun, W., Celentano, D. D., Vlahov, D., and Strathdee, S. A. (2003). Attitudes toward HIV treatments influence unsafe sexual and injection practices among injection drug users. AIDS, 17, 1953–1962.PubMedCrossRef
22.
Weinhardt, L. S., Kelly, J. A., Brondino, M. J., Rotheram–Borus, M. J., Kirshenbaum, S. B., and Chesney, M. A. (2004). HIV transmission risk behavior among men and women living with HIV in 4 cities in the United States. Journal of Acquired Immune Deficiency Syndromes, 36, 1057–1066.PubMed
Metadata
Title
Providers’ HIV Prevention Discussions with HIV-Seropositive Injection Drug Users
Authors
James D. Wilkinson
Wei Zhao
Scott Santibanez
Julia Arnsten
Amy Knowlton
Cynthia A. Gómez
Lisa R. Metsch
INSPIRE Study Group
Publication date
01-11-2006
Published in
AIDS and Behavior / Issue 6/2006
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-006-9088-4

Other articles of this Issue 6/2006

AIDS and Behavior 6/2006 Go to the issue

Original Article

Contextual Determinants of Condom Use Among Female Sex Exchangers in East Harlem, NYC: An Event Analysis

Original Paper

Gender differences in sexual behaviors, sexual partnerships, and HIV among drug users in New York City

Original Paper

Towards a Definition of Orphaned and Vulnerable Children

Original Article

New York City Injection Drug Users’ Memories of Syringe-Sharing Patterns and Changes During the Peak of the HIV/AIDS Epidemic

Original Artical

Inconsistent Condom Use with Steady and Casual Partners and Associated Factors among Sexually-Active Men who Have Sex with Men in Bangkok, Thailand

Original Paper

Feasibility and Use of School-Based Condom Availability Programs in Tijuana, Mexico
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits